State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of New Drug Research and Development, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Department of Biology, Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen Key Laboratory of Cell Microenvironment and SUSTech-HKU joint laboratories for matrix biology, Southern University of Science and Technology, Shenzhen 518055, China.
Curr Med Chem. 2020;27(7):1132-1150. doi: 10.2174/0929867325666181008143411.
Antibiotic resistance is currently a serious problem for global public health. To this end, discovery of new antibacterial drugs that interact with novel targets is important. The biosynthesis of lipoproteins is vital to bacterial survival and its inhibitors have shown efficacy against a range of bacteria, thus bacterial lipoprotein biosynthetic pathway is a potential target.
At first, the literature that covered the basic concept of bacterial lipoprotein biosynthetic pathway as well as biochemical characterization of three key enzymes was reviewed. Then, the recently resolved crystal structures of the three enzymes were retrieved from Protein Data Bank (PDB) and the essential residues in the active sites were analyzed. Lastly, all the available specific inhibitors targeting this pathway and their Structure-activity Relationship (SAR) were discussed.
We briefly introduce the bacterial lipoprotein biosynthetic pathway and describe the structures and functions of three key enzymes in detail. In addition, we present much knowledge on ligand recognition that may facilitate structure-based drug design. Moreover, we focus on the SAR of LspA inhibitors and discuss their potency and drug-likeness.
This review presents a clear background of lipoprotein biosynthetic pathway and provides practical clues for structure-based drug design. In particular, the most up-to-date knowledge on the SAR of lead compounds targeting this pathway would be a good reference for discovery of a novel class of antibacterial agents.
抗生素耐药性目前是全球公共卫生面临的严重问题。为此,发现与新靶标相互作用的新型抗菌药物非常重要。脂蛋白的生物合成对细菌的生存至关重要,其抑制剂已显示出对多种细菌的疗效,因此细菌脂蛋白生物合成途径是一个潜在的靶标。
首先,综述了涵盖细菌脂蛋白生物合成途径基本概念以及三种关键酶的生化特征的文献。然后,从蛋白质数据库(PDB)中检索了最近解析的三种酶的晶体结构,并分析了活性部位的必需残基。最后,讨论了针对该途径的所有可用的特异性抑制剂及其结构-活性关系(SAR)。
我们简要介绍了细菌脂蛋白生物合成途径,并详细描述了三种关键酶的结构和功能。此外,我们还介绍了配体识别方面的大量知识,这可能有助于基于结构的药物设计。此外,我们重点介绍了 LspA 抑制剂的 SAR,并讨论了它们的效力和类药性。
本综述提供了脂蛋白生物合成途径的清晰背景,并为基于结构的药物设计提供了实用线索。特别是,针对该途径的先导化合物 SAR 的最新知识将为发现新型抗菌药物提供很好的参考。